Cargando…
Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
For decades, the prognosis for patients with advanced-stage non–small cell lung cancer (NSCLC) was bleak, with chemotherapy offering limited benefit and much toxicity. Now, with mutational testing, new generations of targeted therapies, and emerging immunotherapies, the treatment horizon for these p...
Autores principales: | Waxman, Elizabeth S., Fossella, Frank V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737399/ https://www.ncbi.nlm.nih.gov/pubmed/29282427 |
Ejemplares similares
-
Advances in the Use of Targeted Therapies in the Management of Non–Small Cell Lung Cancer
por: Wakelee, Heather, et al.
Publicado: (2018) -
Biomarkers of immunotherapy in non-small cell lung cancer
por: Wang, Lingling, et al.
Publicado: (2020) -
Integrating endobronchial ultrasound bronchoscopy with molecular testing of immunotherapy biomarkers in non-small cell lung cancer
por: Bozinovski, Steven, et al.
Publicado: (2021) -
Immunotherapy and the Treatment of Non–Small Cell Lung Cancer
por: Walker, Suzanne
Publicado: (2016) -
Targeted therapies and immunotherapy in non-small-cell lung cancer
por: Cortinovis, D, et al.
Publicado: (2016)